• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

CA19-9 as a screening and diagnostic tool in symptomatic patients: the Japanese experience.

作者信息

Satake K, Takeuchi T, Homma T, Ozaki H

机构信息

First Department of Surgery, Osaka City University Medical School, Japan.

出版信息

Pancreas. 1994 Nov;9(6):703-6. doi: 10.1097/00006676-199411000-00005.

DOI:10.1097/00006676-199411000-00005
PMID:7846012
Abstract

Although the prognosis for pancreatic cancer is generally poor, the Japanese Pancreatic Cancer Register reported in 1992 that the survival rate for resected pancreatic cancer was much higher than that for more conservative treatment. T1 and T2 pancreatic tumors are much more frequently resectable than are T3 and T4 tumors, and the 5-year survival rate for unresected T2, T3, and T4 cases is 0%. These findings emphasize the importance of early diagnosis of resectable pancreatic cancer. CA19-9 has shown satisfactory sensitivity in detecting advanced pancreatic cancer; we sought to determine the effectiveness of CA19-9 as part of a screening program for early cancer. Using elastase 1, CA19-9, and ultrasonography, we developed and tested a program of mass screening on persons presenting with and without abdominal complaints.

摘要

相似文献

1
CA19-9 as a screening and diagnostic tool in symptomatic patients: the Japanese experience.
Pancreas. 1994 Nov;9(6):703-6. doi: 10.1097/00006676-199411000-00005.
2
Comparison of CA19-9 with other tumor markers in the diagnosis of cancer of the pancreas.CA19-9与其他肿瘤标志物在胰腺癌诊断中的比较。
Pancreas. 1994 Nov;9(6):720-4. doi: 10.1097/00006676-199411000-00008.
3
Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population.碳水化合物抗原19-9作为无症状人群胰腺癌筛查试验的临床实用性。
J Gastroenterol Hepatol. 2004 Feb;19(2):182-6. doi: 10.1111/j.1440-1746.2004.03219.x.
4
Applicative Value of Serum CA19-9, CEA, CA125 and CA242 in Diagnosis and Prognosis for Patients with Pancreatic Cancer Treated by Concurrent Chemoradiotherapy.血清CA19-9、CEA、CA125和CA242在同步放化疗治疗的胰腺癌患者诊断及预后中的应用价值
Asian Pac J Cancer Prev. 2015;16(15):6569-73. doi: 10.7314/apjcp.2015.16.15.6569.
5
Evaluation of serum D-dimer, fibrinogen, and CA19-9 for postoperative monitoring and survival prediction in resectable pancreatic carcinoma.血清D-二聚体、纤维蛋白原和CA19-9在可切除胰腺癌术后监测及生存预测中的评估
World J Surg Oncol. 2017 Feb 20;15(1):48. doi: 10.1186/s12957-017-1104-9.
6
Serum CA19-9 is significantly upregulated up to 2 years before diagnosis with pancreatic cancer: implications for early disease detection.血清CA19-9在胰腺癌诊断前长达2年时显著上调:对疾病早期检测的意义。
Clin Cancer Res. 2015 Feb 1;21(3):622-31. doi: 10.1158/1078-0432.CCR-14-0365. Epub 2014 Jun 17.
7
Diagnosis of pancreatic cancer and prediction of unresectability using the tumor-associated antigen CA19-9.利用肿瘤相关抗原CA19-9诊断胰腺癌及预测不可切除性
Pancreas. 1994 Nov;9(6):731-4. doi: 10.1097/00006676-199411000-00010.
8
CA19-9 capability as predictor of pancreatic cancer resectability in a Spanish cohort.CA19-9 能力可预测西班牙队列中胰腺癌的可切除性。
Mol Biol Rep. 2020 Mar;47(3):1583-1588. doi: 10.1007/s11033-020-05245-5. Epub 2020 Jan 8.
9
CA19-9: the Italian experience.CA19-9:意大利的经验。
Pancreas. 1994 Nov;9(6):717-9.
10
Postoperative carcinoembryonic antigen as a complementary tumor marker of carbohydrate antigen 19-9 in pancreatic ductal adenocarcinoma.术后癌胚抗原作为胰腺导管腺癌中糖类抗原19-9的补充肿瘤标志物。
J Korean Med Sci. 2015 Mar;30(3):259-63. doi: 10.3346/jkms.2015.30.3.259. Epub 2015 Feb 16.

引用本文的文献

1
The Role of Resolvin D1 in the Differential Diagnosis of Pancreatic Ductal Adenocarcinoma and Acute Pancreatitis: A Case-Control Study.消退素D1在胰腺导管腺癌与急性胰腺炎鉴别诊断中的作用:一项病例对照研究。
Medicina (Kaunas). 2025 Jan 21;61(2):168. doi: 10.3390/medicina61020168.
2
Imaging Techniques and Biochemical Biomarkers: New Insights into Diagnosis of Pancreatic Cancer.成像技术与生化生物标志物:胰腺癌诊断的新见解
Cell Biochem Biophys. 2024 Dec;82(4):3123-3144. doi: 10.1007/s12013-024-01437-z. Epub 2024 Jul 19.
3
Pancreatic ductal adenocarcinoma: the latest on diagnosis, molecular profiling, and systemic treatments.
胰腺导管腺癌:诊断、分子特征及全身治疗的最新进展
Front Oncol. 2024 Jul 1;14:1386699. doi: 10.3389/fonc.2024.1386699. eCollection 2024.
4
Clinical practice guidelines for molecular tumor marker, 2nd edition review part 2.临床肿瘤分子标志物检测技术指南 第 2 版 解读 2
Int J Clin Oncol. 2024 May;29(5):512-534. doi: 10.1007/s10147-024-02497-0. Epub 2024 Mar 17.
5
Cyfra 21.1: A Useful Tumour Marker in Pancreatic Ductal Adenocarcinoma: Cross-Sectional Study.细胞角蛋白 19 片段 21.1:一种用于胰腺导管腺癌的有用肿瘤标志物:横断面研究。
Cancer Control. 2024 Jan-Dec;31:10732748241228037. doi: 10.1177/10732748241228037.
6
Exploiting the relevance of CA 19-9 in pancreatic cancer.利用CA 19-9在胰腺癌中的相关性。
J Cancer Metastasis Treat. 2020;6. doi: 10.20517/2394-4722.2020.70. Epub 2020 Sep 17.
7
Earlier Diagnosis of Pancreatic Cancer: Is It Possible?胰腺癌的早期诊断:是否可行?
Cancers (Basel). 2023 Sep 5;15(18):4430. doi: 10.3390/cancers15184430.
8
Clinical significance of tumor markers in patients with type 2 diabetes: a retrospective observational study.2型糖尿病患者肿瘤标志物的临床意义:一项回顾性观察研究。
Diabetol Int. 2022 Jul 12;14(1):40-50. doi: 10.1007/s13340-022-00594-x. eCollection 2023 Jan.
9
Clinical Clues of Pre-Symptomatic Pancreatic Ductal Adenocarcinoma Prior to Its Diagnosis: A Retrospective Review of CT Scans and Laboratory Tests.症状前胰腺导管腺癌诊断前的临床线索:CT扫描和实验室检查的回顾性分析
Clin Pract. 2022 Jan 17;12(1):70-77. doi: 10.3390/clinpract12010008.
10
The Impact of Biomarkers in Pancreatic Ductal Adenocarcinoma on Diagnosis, Surveillance and Therapy.生物标志物在胰腺导管腺癌中对诊断、监测及治疗的影响
Cancers (Basel). 2022 Jan 3;14(1):217. doi: 10.3390/cancers14010217.